Latest Breaking News On - Michele parisi - Page 7 : comparemela.com

Share this article Share this article AUSTIN, Texas, March 4, 2021 /PRNewswire/ Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG ® Respiratory Pathogen Panel (RPP) that includes the SARS-CoV-2 virus for high-throughput respiratory testing. The new test is a combination of the company s original NxTAG RPP, an FDA-cleared in vitro diagnostic for syndromic respiratory infection testing, and SARS-CoV-2. Respiratory infections such as COVID-19 and influenza can be challenging to differentiate and diagnose because they often have overlapping symptoms. NxTAG RPP is a multiplex, high-throughput test designed to enable simultaneous detection of the most common respiratory pathogens for a fast, syndromic testing approach. Following the addition of the SARS-CoV-2 virus target, the panel now includes 19 viral and 2 bacterial targets, combining

South africaUnited statesUnited kingdomHarriss currieMichele parisiNachum homi shamirPrnewswire luminex corporationHuman servicesBiomedical advanced researchDrug administrationDevelopment authorityPathogen panelNxtag cov extended panelDivision of research innovationDepartment of healthOffice of the